{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:17:53Z","timestamp":1758845873514,"version":"3.44.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,25]]},"DOI":"10.7759\/cureus.93183","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:48:37Z","timestamp":1758804517000},"source":"Crossref","is-referenced-by-count":0,"title":["A Systematic Review and Meta-Analysis of Cannabis Use Frequency and Metabolic Dysfunction-Associated Steatotic Liver Disease: Scapegoat or Healer?"],"prefix":"10.7759","author":[{"given":"N\u00e9stor Israel","family":"Quinapanta Castro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdel","family":"Berm\u00fadez-del Sol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25042370","article-title":"The role of cannabidiol in liver disease: a systemic review","volume":"25","author":"Chen S","year":"2024","unstructured":"Chen S, Kim JK. The role of cannabidiol in liver disease: a systemic review. Int J Mol Sci. 2024, 25:2370. 10.3390\/ijms25042370","journal-title":"Int J Mol Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2024.103043","article-title":"Global prevalence of nonalcoholic fatty liver disease: an updated review meta-analysis comprising a population of 78 million from 38 countries","volume":"55","author":"Amini-Salehi E","year":"2024","unstructured":"Amini-Salehi E, Letafatkar N, Norouzi N, et al.. Global prevalence of nonalcoholic fatty liver disease: an updated review meta-analysis comprising a population of 78 million from 38 countries. Arch Med Res. 2024, 55:103043. 10.1016\/j.arcmed.2024.103043","journal-title":"Arch Med Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.04.036","article-title":"Changing epidemiology, global trends and implications for outcomes of NAFLD","volume":"79","author":"Wong VW","year":"2023","unstructured":"Wong VW, Ekstedt M, Wong GL, Hagstr\u00f6m H. Changing epidemiology, global trends and implications for outcomes of NAFLD. J Hepatol. 2023, 79:842-52. 10.1016\/j.jhep.2023.04.036","journal-title":"J Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi ZM","year":"2025","unstructured":"Younossi ZM, Kalligeros M, Henry L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. 2025, 31:S32-50. 10.3350\/cmh.2024.0431","journal-title":"Clin Mol Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.742382","article-title":"Non-alcoholic steatohepatitis pathogenesis, diagnosis, and treatment","volume":"8","author":"Zhu B","year":"2021","unstructured":"Zhu B, Chan SL, Li J, Li K, Wu H, Cui K, Chen H. Non-alcoholic steatohepatitis pathogenesis, diagnosis, and treatment. Front Cardiovasc Med. 2021, 8:742382. 10.3389\/fcvm.2021.742382","journal-title":"Front Cardiovasc Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e28468","article-title":"Nonalcoholic steatohepatitis: a comprehensive updated review of risk factors, symptoms, and treatment","volume":"10","author":"Savari F","year":"2024","unstructured":"Savari F, Mard SA. Nonalcoholic steatohepatitis: a comprehensive updated review of risk factors, symptoms, and treatment. Heliyon. 2024, 10:e28468. 10.1016\/j.heliyon.2024.e28468","journal-title":"Heliyon"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0365","article-title":"Global incidence and prevalence of nonalcoholic fatty liver disease","volume":"29","author":"Teng ML","year":"2023","unstructured":"Teng ML, Ng CH, Huang DQ, et al.. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2023, 29:S32-42. 10.3350\/cmh.2022.0365","journal-title":"Clin Mol Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi ZM","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023, 77:1335-47. 10.1097\/HEP.0000000000000004","journal-title":"Hepatology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2010.02352.x","article-title":"Cross-regulation of cannabinoid CB1 and CB2 receptors governs hepatic steatosis","volume":"30","author":"Yang YY","year":"2010","unstructured":"Yang YY, Lin HC. Cross-regulation of cannabinoid CB1 and CB2 receptors governs hepatic steatosis. Liver Int. 2010, 30:1397-9. 10.1111\/j.1478-3231.2010.02352.x","journal-title":"Liver Int"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn.2018.12.05","article-title":"Nonalcoholic fatty liver disease (NAFLD) prevention: role of Mediterranean diet and physical activity","volume":"8","author":"Trovato FM","year":"2019","unstructured":"Trovato FM, Castrogiovanni P, Malatino L, Musumeci G. Nonalcoholic fatty liver disease (NAFLD) prevention: role of Mediterranean diet and physical activity. Hepatobiliary Surg Nutr. 2019, 8:167-9. 10.21037\/hbsn.2018.12.05","journal-title":"Hepatobiliary Surg Nutr"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4103\/1319-3767.114505","article-title":"The role of endocannabinoids system in fatty liver disease and therapeutic potentials","volume":"19","author":"Alswat KA","year":"2013","unstructured":"Alswat KA. The role of endocannabinoids system in fatty liver disease and therapeutic potentials. Saudi J Gastroenterol. 2013, 19:144-51. 10.4103\/1319-3767.114505","journal-title":"Saudi J Gastroenterol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S1262-3636(08)74604-4","article-title":"Cannabinoid receptors as novel therapeutic targets for the management of non-alcoholic steatohepatitis","volume":"34","author":"Mallat A","year":"2008","unstructured":"Mallat A, Lotersztajn S. Cannabinoid receptors as novel therapeutic targets for the management of non-alcoholic steatohepatitis. Diabetes Metab. 2008, 34:680-4. 10.1016\/S1262-3636(08)74604-4","journal-title":"Diabetes Metab"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000003355","article-title":"Drug treatment for metabolic dysfunction-associated steatotic liver disease: progress and direction","volume":"137","author":"Zhou D","year":"2024","unstructured":"Zhou D, Fan J. Drug treatment for metabolic dysfunction-associated steatotic liver disease: progress and direction. Chin Med J (Engl). 2024, 137:2687-96. 10.1097\/CM9.0000000000003355","journal-title":"Chin Med J (Engl)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.7973","article-title":"Association between cannabis use and risk of diabetes mellitus type 2: a systematic review and meta-analysis","volume":"37","author":"Mousavi SE","year":"2023","unstructured":"Mousavi SE, Tondro Anamag F, Sanaie S. Association between cannabis use and risk of diabetes mellitus type 2: a systematic review and meta-analysis. Phytother Res. 2023, 37:5092-108. 10.1002\/ptr.7973","journal-title":"Phytother Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1089\/can.2021.0094","article-title":"Cannabis use is inversely associated with overweight and obesity in hepatitis B virus-infected patients (ANRS CO22 Hepather Cohort)","volume":"7","author":"Barr\u00e9 T","year":"2022","unstructured":"Barr\u00e9 T, Pol S, Ramier C, et al.. Cannabis use is inversely associated with overweight and obesity in hepatitis B virus-infected patients (ANRS CO22 Hepather Cohort). Cannabis Cannabinoid Res. 2022, 7:677-89. 10.1089\/can.2021.0094","journal-title":"Cannabis Cannabinoid Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000001263","article-title":"Marijuana is not associated with progression of hepatic fibrosis in liver disease: a systematic review and meta-analysis","volume":"31","author":"Farooqui MT","year":"2019","unstructured":"Farooqui MT, Khan MA, Cholankeril G, et al.. Marijuana is not associated with progression of hepatic fibrosis in liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2019, 31:149-56. 10.1097\/MEG.0000000000001263","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2019.109677","article-title":"Cannabis consumption and non-alcoholic fatty liver disease. A three years longitudinal study in first episode non-affective psychosis patients","volume":"95","author":"V\u00e1zquez-Bourgon J","year":"2019","unstructured":"V\u00e1zquez-Bourgon J, Ortiz-Garc\u00eda de la Foz V, Suarez-Pereira I, et al.. Cannabis consumption and non-alcoholic fatty liver disease. A three years longitudinal study in first episode non-affective psychosis patients. Prog Neuropsychopharmacol Biol Psychiatry. 2019, 95:109677. 10.1016\/j.pnpbp.2019.109677","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/804969","article-title":"Marijuana use in hepatitis C infection does not affect liver biopsy histology or treatment outcomes","volume":"28","author":"Liu T","year":"2014","unstructured":"Liu T, Howell GT, Turner L, Corace K, Garber G, Cooper C. Marijuana use in hepatitis C infection does not affect liver biopsy histology or treatment outcomes. Can J Gastroenterol Hepatol. 2014, 28:381-4. 10.1155\/2014\/804969","journal-title":"Can J Gastroenterol Hepatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.11.039","article-title":"Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C","volume":"134","author":"H\u00e9zode C","year":"2008","unstructured":"H\u00e9zode C, Zafrani ES, Roudot-Thoraval F, et al.. Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology. 2008, 134:432-9. 10.1053\/j.gastro.2007.11.039","journal-title":"Gastroenterology"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0284859","article-title":"Marijuana use is inversely associated with liver steatosis detected by transient elastography in the general United States population in NHANES 2017-2018: a cross-sectional study","volume":"18","author":"Du R","year":"2023","unstructured":"Du R, Tang XY, Yang C, Gao WH, Gao SJ, Xiang HJ, Yang L. Marijuana use is inversely associated with liver steatosis detected by transient elastography in the general United States population in NHANES 2017-2018: a cross-sectional study. PLoS ONE. 2023, 18:e0284859. 10.1371\/journal.pone.0284859","journal-title":"PLoS ONE"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2021.1884545","article-title":"Cannabis use and reduced risk of elevated fatty liver index in HIV-HCV co-infected patients: a longitudinal analysis (ANRS CO13 HEPAVIH)","volume":"19","author":"Barr\u00e9 T","year":"2021","unstructured":"Barr\u00e9 T, Rojas Rojas T, Lacombe K, et al.. Cannabis use and reduced risk of elevated fatty liver index in HIV-HCV co-infected patients: a longitudinal analysis (ANRS CO13 HEPAVIH). Expert Rev Anti Infect Ther. 2021, 19:1147-56. 10.1080\/14787210.2021.1884545","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186702","article-title":"Inverse association of marijuana use with nonalcoholic fatty liver disease among adults in the United States","volume":"12","author":"Kim D","year":"2017","unstructured":"Kim D, Kim W, Kwak MS, Chung GE, Yim JY, Ahmed A. Inverse association of marijuana use with nonalcoholic fatty liver disease among adults in the United States. PLoS ONE. 2017, 12:e0186702. 10.1371\/journal.pone.0186702","journal-title":"PLoS ONE"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12797","article-title":"Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus-co-infected patients (ANRS CO13-HEPAVIH)","volume":"25","author":"Nordmann S","year":"2018","unstructured":"Nordmann S, Vilotitch A, Roux P, et al.. Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus-co-infected patients (ANRS CO13-HEPAVIH). J Viral Hepat. 2018, 25:171-9. 10.1111\/jvh.12797","journal-title":"J Viral Hepat"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176416","article-title":"Cannabis use is associated with reduced prevalence of non-alcoholic fatty liver disease: a cross-sectional study","volume":"12","author":"Adejumo AC","year":"2017","unstructured":"Adejumo AC, Alliu S, Ajayi TO, et al.. Cannabis use is associated with reduced prevalence of non-alcoholic fatty liver disease: a cross-sectional study. PLoS ONE. 2017, 12:e0176416. 10.1371\/journal.pone.0176416","journal-title":"PLoS ONE"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr4165","article-title":"Associations between cannabis use, abdominal fat phenotypes and insulin traits","volume":"12","author":"Stuart CE","year":"2020","unstructured":"Stuart CE, Ko J, Alarcon Ramos GC, Modesto AE, Cho J, Petrov MS. Associations between cannabis use, abdominal fat phenotypes and insulin traits. J Clin Med Res. 2020, 12:377-88. 10.14740\/jocmr4165","journal-title":"J Clin Med Res"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2303","article-title":"Metabolic effects of chronic cannabis smoking","volume":"36","author":"Muniyappa R","year":"2013","unstructured":"Muniyappa R, Sable S, Ouwerkerk R, et al.. Metabolic effects of chronic cannabis smoking. Diabetes Care. 2013, 36:2415-22. 10.2337\/dc12-2303","journal-title":"Diabetes Care"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1089\/can.2024.0027","article-title":"Associations of cannabis use, metabolic dysfunction-associated steatotic liver disease, and liver fibrosis in U.S. adults","volume":"10","author":"Wu Y","year":"2025","unstructured":"Wu Y, Fang F, Fan X, Nie H. Associations of cannabis use, metabolic dysfunction-associated steatotic liver disease, and liver fibrosis in U.S. adults. Cannabis Cannabinoid Res. 2025, 10:527-36. 10.1089\/can.2024.0027","journal-title":"Cannabis Cannabinoid Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1089\/can.2018.0045","article-title":"Theoretical explanation for reduced body mass index and obesity rates in cannabis users","volume":"3","author":"Clark TM","year":"2018","unstructured":"Clark TM, Jones JM, Hall AG, Tabner SA, Kmiec RL. Theoretical explanation for reduced body mass index and obesity rates in cannabis users. Cannabis Cannabinoid Res. 2018, 3:259-71. 10.1089\/can.2018.0045","journal-title":"Cannabis Cannabinoid Res"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.63019","article-title":"Relationship between metabolic dysfunction-associated steatotic liver disease and lipoprotein (a) and other biomarkers","volume":"16","author":"Mu\u00f1oz Rossi FA","year":"2024","unstructured":"Mu\u00f1oz Rossi FA, Salazar Agudelo J, Quinapanta Castro NI, et al.. Relationship between metabolic dysfunction-associated steatotic liver disease and lipoprotein (a) and other biomarkers. Cureus. 2024, 16:e63019. 10.7759\/cureus.63019","journal-title":"Cureus"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.28728","article-title":"Cannabidiol protects livers against nonalcoholic steatohepatitis induced by high-fat high cholesterol diet via regulating NF-\u03baB and NLRP3 inflammasome pathway","volume":"234","author":"Huang Y","year":"2019","unstructured":"Huang Y, Wan T, Pang N, et al.. Cannabidiol protects livers against nonalcoholic steatohepatitis induced by high-fat high cholesterol diet via regulating NF-\u03baB and NLRP3 inflammasome pathway. J Cell Physiol. 2019, 234:21224-34. 10.1002\/jcp.28728","journal-title":"J Cell Physiol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.2174\/2210315513666230526100544","article-title":"Cannabidiol and indole-3-carbinol reduce intracellular lipid droplet accumulation in HepaRG, a human liver cell line, as well as in human adipocytes","volume":"14","author":"Senthilkumar S","year":"2024","unstructured":"Senthilkumar S, Solan ME, Fernandez-Luna MT, et al.. Cannabidiol and indole-3-carbinol reduce intracellular lipid droplet accumulation in HepaRG, a human liver cell line, as well as in human adipocytes. Nat Prod J. 2024, 14:10.2174\/2210315513666230526100544","journal-title":"Nat Prod J"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2013.12.026","article-title":"Cannabidiol protects liver from binge alcohol-induced steatosis by mechanisms including inhibition of oxidative stress and increase in autophagy","volume":"68","author":"Yang L","year":"2014","unstructured":"Yang L, Rozenfeld R, Wu D, Devi LA, Zhang Z, Cederbaum A. Cannabidiol protects liver from binge alcohol-induced steatosis by mechanisms including inhibition of oxidative stress and increase in autophagy. Free Radic Biol Med. 2014, 68:260-7. 10.1016\/j.freeradbiomed.2013.12.026","journal-title":"Free Radic Biol Med"},{"key":"ref33","article-title":"How harmful is marijuana?","author":"Mack A","year":"2000","unstructured":"Mack A, Joy J. How harmful is marijuana?. Marijuana as Medicine?: The Science Beyond the Controversy. National Academies Press (US), Washington (DC); 2000."},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01481","article-title":"Harmful effects of smoking cannabis: a cerebrovascular and neurological perspective","volume":"10","author":"Archie SR","year":"2019","unstructured":"Archie SR, Cucullo L. Harmful effects of smoking cannabis: a cerebrovascular and neurological perspective. Front Pharmacol. 2019, 10:1481. 10.3389\/fphar.2019.01481","journal-title":"Front Pharmacol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000686","article-title":"Effects of marijuana on reproductive health: preconception and gestational effects","volume":"28","author":"Ryan KS","year":"2021","unstructured":"Ryan KS, Bash JC, Hanna CB, Hedges JC, Lo JO. Effects of marijuana on reproductive health: preconception and gestational effects. Curr Opin Endocrinol Diabetes Obes. 2021, 28:558-65. 10.1097\/MED.0000000000000686","journal-title":"Curr Opin Endocrinol Diabetes Obes"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/394896-a-systematic-review-and-meta-analysis-of-cannabis-use-frequency-and-metabolic-dysfunction-associated-steatotic-liver-disease-scapegoat-or-healer","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:48:38Z","timestamp":1758804518000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/394896-a-systematic-review-and-meta-analysis-of-cannabis-use-frequency-and-metabolic-dysfunction-associated-steatotic-liver-disease-scapegoat-or-healer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":35,"URL":"https:\/\/doi.org\/10.7759\/cureus.93183","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,25]]}}}